View Older Stories View More Recent Stories

Dec 4, 2023 08:00AM Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Nov 20, 2023 08:00AM Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
Nov 13, 2023 08:00AM Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
Nov 9, 2023 08:00AM Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
Nov 6, 2023 08:00AM Daré Bioscience to Participate in Three November Conferences
Nov 2, 2023 08:00AM Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023
Nov 1, 2023 08:01AM Dare Bioscience (DARE) Reports Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream
Nov 1, 2023 08:00AM Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
Oct 16, 2023 08:07AM Dare Bioscience (DARE) Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO Vaginal Gel, 2%
Oct 16, 2023 08:00AM Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in F
Sep 21, 2023 08:04AM Dare Bioscience (DARE) Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Sep 21, 2023 08:00AM Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Sep 20, 2023 08:00AM Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting
Sep 6, 2023 08:00AM Daré Bioscience to Participate in Upcoming Investor Conferences
Sep 5, 2023 08:00AM Daré Bioscience Completes Previously Announced Equity Financing
Aug 30, 2023 08:00AM Dare Bioscience (DARE) Announces 10M Share Offering at $0.70/sh
Aug 30, 2023 08:00AM Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Aug 10, 2023 08:00AM Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
Aug 9, 2023 08:01AM Dare Bioscience (DARE) Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Tri
Aug 9, 2023 08:00AM Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of
Aug 3, 2023 08:00AM Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
Jul 31, 2023 08:00AM Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
Jul 11, 2023 05:30PM Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
Jul 11, 2023 08:00AM Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
Jul 6, 2023 08:00AM Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Jul 5, 2023 08:00AM Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vagino
Jun 21, 2023 08:00AM Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Pos
Jun 14, 2023 08:00AM Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference
Jun 9, 2023 08:00AM Dare Bioscience (DARE) Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1
Jun 9, 2023 08:00AM Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, t
Jun 5, 2023 08:03AM Dare Bioscience (DARE) Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study
Jun 5, 2023 08:00AM Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Jun 1, 2023 08:00AM Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference
May 31, 2023 08:00AM Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine
May 11, 2023 08:00AM Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update
May 4, 2023 08:00AM Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023
Apr 20, 2023 08:00AM Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
Apr 19, 2023 08:00AM David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany
Apr 18, 2023 08:01AM Dare Bioscience (DARE) Announces Publication of Positive Safety and Acceptability Data from Phase 1 Trial of DARE-HRT1
Apr 18, 2023 08:00AM Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Thera
Apr 17, 2023 08:00AM Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
Mar 30, 2023 08:00AM Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
Mar 23, 2023 08:00AM Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
Mar 1, 2023 08:00AM Daré Bioscience to Present at the 35th Annual Roth Conference
Feb 22, 2023 08:00AM Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
Feb 1, 2023 08:00AM Daré Bioscience to Participate in Three February Conferences
Jan 26, 2023 08:01AM Dare Bioscience (DARE) Announces Publication of Data from Phase 1 Trial of DARE-HRT1
Jan 26, 2023 08:00AM Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective
Jan 9, 2023 08:01AM Dare Bioscience (DARE) Reports Positive PK Results from the DARE-HRT1 Phase 1/2 Study
Jan 9, 2023 08:00AM Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vag
View More Recent Stories View Older Stories